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Abstract 
 
We define a new parameter to quantify the antigenic distance between two H3N2 
influenza strains: we use this parameter to measure antigenic distance between circulating 
H3N2 strains and the closest vaccine component of the influenza vaccine. For the data 
between 1971 and 2004, the measure of antigenic distance correlates better with efficacy 
in humans of the H3N2 influenza A annual vaccine than do current state of the art 
measures of antigenic distance such as phylogenetic sequence analysis or ferret antisera 
inhibition assays.  We suggest that this measure of antigenic distance could be used to 
guide the design of the annual flu vaccine. We combine the measure of antigenic distance 
with a multiple-strain avian influenza transmission model to study the threat of 
simultaneous introduction of multiple avian influenza strains. For H3N2 influenza, the 
model is validated against observed viral fixation rates and epidemic progression rates 
from the World Health Organization FluNet – Global Influenza Surveillance Network. 
We find that a multiple-component avian influenza vaccine is helpful to control a 
simultaneous multiple introduction of bird-flu strains. We introduce Population at Risk 
(PaR) to quantify the risk of a flu pandemic, and calculate by this metric the improvement 
that a multiple vaccine offers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Computer-assisted vaccine design 
 
Introduction  
 
Circulating influenza virus uses the ability to change its surface proteins, along with its 
high transmission rate, to flummox the adaptive immune response of the host. The 
random accumulation of mutations in the hemagglutinin (HA) and neuraminidase (NA) 
epitopes, the regions on surface of the viral proteins that are recognized by host 
antibodies, pose a formidable challenge to the design of an effective annual flu vaccine. 
Under current practice, the World Health Organization (WHO), and the respective 
government health agencies, rely on historical experience and phylogenetic analysis of 
HA and NA protein sequences from the circulating human strains to decide upon the 
components in the annual influenza vaccine [Munoz et. al., 2003]. Every year, the 
concerned authorities make a projection about the circulating influenza strains for the 
coming flu season. The flu vaccine currently contains three strains that are as similar as 
possible to those strains that are predicted to be the most prominent. At present, the three 
strains in the vaccine are one H3N2 A, one H1N1 A, and one influenza B component. 
Historically, the vaccine efficacy has seldom reached the 100% mark. Over the years, it 
has hovered between 30-60% against influenza-like illnesses. In fact, due to a 
phenomenon known as the ‘original antigenic sin’ [Davenport et. al., 1953; Fazekas et. 
al., 1966; Deem et. al., 2003], the vaccine efficacy has even been negative at times. If 
original antigenic sin is operative, the host antibodies that are produced in response to a 
viral strain tend to suppress creation of new and different antibodies in response to a 
different viral strain. Whether such a phenomenon takes place or whether the vaccine is 
effective depends to a great extent on how similar the vaccine component strains are to 
the circulating viral strains. The methods employed to calculate such an antigenic 
distance draw heavily from the ferret antisera hemagglutinin inhibition assays. It has been 
assumed that the antigenic distance thus obtained from ferrets correlates well with the 
efficacy of the influenza vaccine in humans. However, to our knowledge there is limited 
evidence in the literature of such correlations. 
 
We introduce the reader to a new and effective way of measuring the antigenic distance 
between different strains. We define a quantity, pepitope, that measures the difference 
between the dominant epitope regions of the hemagglutinin proteins of any two H3N2 
influenza viruses in general. The term pepitope can be used to measure difference between 
the dominant epitope of the H3N2 vaccine component and the dominant circulating viral 
strain. A dominant epitope is one that elicits the most significant response from the 
adaptive immune system for a particular strain in a particular year [Fitch et. al., 1991; 
Bush et. al., 1999; Fitch et. al., 2000; Plotkin et. al., 2003]. We show that for data 
spanning last 35 years, the pepitope measure of antigenic distance correlates better with the 
efficacy studies in humans of the influenza vaccine than do the current measures of 
antigenic distance, even those derived from ferret animal model studies.  The pepitope 
measurement can also be used to measure difference between two circulating viral 
  
strains. The pepitope measurement can give us an idea of antigenic variability of circulating 
influenza strains. 
 
Methods 
 
We have developed a statistical mechanics based theory to model the response of an 
immune system, free of immunoscenescence, to disease and vaccination. We compare 
this theory to experimental studies of vaccine efficacies for 18-64 year old subjects over 
the past 35 years, when the H3N2 subtype of influenza A was the dominant strain. H3N2 
is the most common stain and has caused significant morbidity and mortality [Macken et. 
al., 2001]. As is the norm, we focused on the five epitopes of the hemagglutinin protein. 
We used the generalized NK model to calculate the affinity constants quantifying the 
immune response following exposure to an antigen after vaccination. The model takes 
into account three types of interactions within an antibody. These include interactions 
within subdomains, interactions between different subdomains, and interaction between 
an antibody and an antigen [Jun et. al., 2005]. The binding constant is given as K = exp 
(a-b<U>), where U is the energy function of an antibody [Deem et. al. 2003], a = -18.56, 
and b = 1.67. The values of the constants are determined after comparing the dynamics of 
the model with experimental results [Deem et. al., 2003]. In order to capture the antigenic 
distance between the vaccine strain and the circulating strain, we use pepitope as an order 
parameter in our model. It represents the fraction of amino acids that differ between the 
dominant epitope regions of the two strains.  
 
epitopedominantthein   
acidsaminoofnumbertotal
epitopedominantthein       
sdifferenceacidaminoofnumber
epitope =p                                                                     (1) 
 
In order to build the model we needed the identity and sequence of the dominant epitope 
in both the candidate vaccine and the circulating strain. This definition of the five 
epitopes in the H3N2 hemagglutinin protein was taken from reference [Macken et. al., 
2001]. Our model assumes the following correlation between the vaccine efficacy, E, and 
the binding constants. E = α ln[Ksecondary (pepitope) / Kprimary], where the constant α is 
selected such that a perfect match between the vaccine and the circulating strain 
corresponds to the average historical vaccine efficacy of 45% [Gupta et. al., 2006].  
Kprimary is the binding constant corresponding to the primary immune response, and 
Ksecondary is the binding constant corresponding to the secondary immune response that 
follows vaccination. Other than the constant, α, no parameter was fit to data, making the 
model predictive. For example, the point where vaccine efficacy becomes zero is 
independent of the value of α. 
 
Results 
 
Table 1 compares vaccine efficacy values from experimental studies [Smith et. al., 1979; 
Clements et. al., 1986; Keitel et. al., 1988; Edwards et. al., 1994; Nichol et. al., 1995; 
  
Keitel et. al., 1997; Campbell et. al., 1997; Grotto et. al., 1998; Bridges et. al., 2000; 
Mixeu et. al., 2002; Millot et. al., 2002; Kawai et. al., 2003; Lester et. al., 2003; Dolan et. 
al., 2004] and predictions from our theory as a function of the pepitope. In literature, vaccine 
efficacy is defined as 
,
u
vuEfficiency −=                                                                                                            (2) 
where u and v are the influenza-like illness rates in unvaccinated and vaccinated 
individuals, respectively. The epidemiological estimates of u and v contain some noise; 
however, these are the best estimates there are of influenza vaccine efficacy in humans. 
Our model demonstrates the effectiveness of using pepitope as a measure of antigenic drift 
between the circulating strain and the vaccine strain. Crystallographic data and 
immunoassays have shown that only the epitope regions of the viral proteins are 
significantly involved in the recognition of the antigen via the antibodies [Air et. al., 
1985]. Our definition of pepitope follows from this observation. When pepitope value in the 
dominant epitope is greater than 0.19 according to experimental records or is greater than 
0.22 according to our theory, the efficacy of the influenza vaccine drops to the negative 
territory [Table 1 and Figure 1a] indicating that while designing the vaccine, this regime 
needs to be avoided. As an example, during the 1997/98 influenza season in the Northern 
hemisphere, when the Sydney/5/97 strain was widespread, the value of pepitope was 0.238 
resulting in an efficacy of -17% [Bridges et. al., 2000]. Only one data point falls outside 
our theoretical predications, that for the 1989/90 epidemic [Nguyen-Van-Tran et. al., 
2003]. During that year there were likely multiple strains circulating, including the strains 
of influenza B [Edwards et. al., 1994; Ikonen et. al., 1996].  
 
The WHO uses as a first approximation an alternative definition of the antigenic drift. It 
considers the sequence difference of the entire hemagglutinin protein of the circulating 
and viral strains. 
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The correlation with the experimentally observed efficacy is not as positive when using 
the psequence definition for the antigenic distance. This conclusion is seen from Table 1 and 
Figure 1b, and it follows from the fact that many domains in the protein are either 
inaccessible to the human antibodies or not recognizable with high probability by them. 
Immune recognition of the epitope regions results in the vaccine efficacy being more 
correlated with the pepitope measure of antigenic distance in Eq. 1 than with the 
approximate measure of distance in Eq. 3. 
 
The gold standard measure of antigenic drift is that derived from ferret antisera [Smith et. 
al., 1999; Lee et. al., 2004]. Comparison of the vaccine efficacy to this measure of 
antigenic drift also shows less than ideal success. From Table 1 and Figure 1c, the 
hemagglutinin assays in ferret antisera are unable to capture a significant amount of 
  
human efficacy information. For example, an antigenic distance of zero according to 
ferret antisera experiments does not mean that the two strains are identical. As an 
example, for the 1996/97 season, the antigenic distance derived from ferret antisera 
between the vaccine strain of A/Nanchang/933/95 and the circulating strain of 
A/Wuhan/359/95 was zero, whereas pepitope value was 0.095. The corresponding vaccine 
efficacy in the Northern and Southern hemispheres was 28% [Millot et. al., 2002] and 
11% [Mixeu et. al., 2002] respectively. When compared to the average efficacy 
corresponding to a perfect match between the vaccine strain and the circulating strain, 
which is 45%, these efficacy values are clearly much lower. Thus, ferret derived 
distances will occasionally misidentify antigenically distant strains as antigenically 
identical. 
 
Discussion 
 
Design of the influenza vaccine is always a race against time. Currently, under the 
supervision of the WHO and the national health agencies, in the Northern hemisphere, 
the components of the annual influenza vaccine are determined between February and 
April.  The mass production of the vaccine is then carried out by growing the virus in 
hen’s eggs. After regulatory tests in mid-July, the vaccine is distributed in September. 
Data are collected to determine the vaccine efficacy starting in October and continuing 
through the Winter flu season. By January a good measure of the effectiveness of the 
season’s vaccine is obtained. Choice of the vaccine strain is contingent up on various 
biological and manufacturing constraints. For example, among the egg-cultured strains, 
the availability of high growth strains is an additional criterion. The organizations in 
charge have to weigh in all these constraints before they decide on the best match for the 
anticipated circulating strain for the following flu season.  
 
The pepitope measure of antigenic distance can influence and contribute to the vaccine 
design process in two ways. First, pepitope can help to identify the strains to be included in 
the annual flu vaccine. For every season, given a list of strains and their probabilities of 
outbreak, the value of pepitope can help define the weighted distance of a particular vaccine 
strain from the circulating strains. This procedure will enable us to identify the vaccine 
strain closest to the strains causing a possible outbreak. Alternately, pepitope can also help 
identify the ‘like’ strains and to quantify ‘likeness.’ Various manufacturing constraints in 
the vaccine production process mean it is often not feasible to grow large quantities of the 
exact strain that is desired for the annual vaccine. Under such scenario, it is required to 
choose several strains that are similar to the chosen one. The value of pepitope can help 
quantify the ‘likenesses’ of a given strain to the desired strain. We can extend pepitope 
measure of antigenic distance to other strains of influenza as well.  Using information 
about the epitope regions of other HxNy strains of influenza A or influenza B, we can 
calculate the value of pepitope to quantify the antigenic distance for these strains of 
influenza. 
 
It is clear that the immune system response is neither linear nor monotonic in the 
antigenic distance. As a result, the original antigenic sin leading to a negative vaccine 
efficacy exists only in an intermediate regime of the antigenic distance. If the vaccine 
  
falls in this regime, however, the vaccinated individual appears to be more susceptible to 
influenza-like illnesses compared to an unvaccinated individual. Over the past 33 years, 
this phenomenon seems to have taken place 26% of the time according to the H3N2 
epidemiological data as indicated by 5 of the total 19 data points that are negative in table 
1 and figure 1.b. The negative points are not necessarily a result of experimental errors; 
rather they may have their roots in the original antigenic sin phenomenon where the 
immune system is unable to distinguish between the new and the old viral strains. It is 
desired that the regime corresponding to the original antigenic sin is avoided, not only for 
the obvious immunological consequences, but also for the negative impact it creates 
against the acceptance of public health policy. Our theory rightfully captures the 
underlying physics of immune response, and corroborates the experimental findings. Our 
theory and pepitope measure of antigenic distance can be used to ensure that vaccines chosen 
would not fall in the original antigenic sin region against expected strains. Saying this 
more conservatively, our theory can be used to ensure that the vaccine strains chosen are 
antigenically close enough to the expected strains so that the vaccine efficacy is expected 
to be positive. 
 
It appears that pepitope is a measure of the antigenic distance between viral strains that 
correlates more strongly with vaccine efficacy than is the sequence analysis or the ferret 
antisera. The population at large may benefit if the health authorities incorporate pepitope in 
the prediction and design of the influenza vaccine in addition to (or even instead of) the 
current practices. We now present an example to show how our theory can assist shaping 
public health policies. We examine the 2004/2005 flu season in the Northern hemisphere. 
With the aid of pepitope we can stipulate a priori the extent of protection that a particular 
vaccine strain provides against the circulating strain for a particular season. The 
comparison among various candidates would provide us selection criteria for their 
inclusion in the annual flu vaccine. During the 2003/2004 flu epidemic, 
A/Fujian/411/2002 strain was predominant, and it was expected that this strain would 
dominant in 2004/2005 as well. In order to counter this strain, the Advisory Council of 
the FDA recommended using A/Wyoming/2003 as the H3N2 component of the 
2004/2005 vaccine, since according to the prevalent measures, this strain and 
A/Fujian/411/2002 were found to be ‘antigenically equivalent’ [Harper et. al., 2004]. Our 
calculations, however, yielded a pepitope value of 0.095 for the pair in question, suggesting 
that the two strains were not antigenically equivalent, and the predicted efficacy is 20% 
(figure 1.a). Also, in 2004/2005, A/California/7/2004 strain was in circulation along with 
significant amount of influenza B. The pepitope value for the pair of A/California/7/2004 
and the A/Wyoming/2003 strain was 0.286. According to our theory the vaccine would 
not have provided a positive protection from the A/California/7/2004 strain. The vaccine 
efficacy that year was 9.2% [Chan et. al., 2008], which is roughly the average of the 
efficacies (0% and 20%) predicted by pepitope theory.  We note that another of the WHO 
approved candidates for that year was A/Kumamoto/102/02 (ISDN38180) [WHO, 2004], 
and we found pepitope value to be zero versus A/Fujian/411/2002. According to our theory, 
a vaccine containing the Kumamoto strain would have provided a better protection 
against the Fujian strain that did the Wyoming vaccine strain.  
 
 
  
Suggestions to improve predictability of vaccine efficacy 
 
At the heart of our approach lies the identification of the dominant hemagglutinin epitope 
recognized in humans. The identity of the dominant epitope for humans is currently not 
measured. We, thus, define and postulate the dominant epitope for humans for a certain 
strain and for a certain season as the epitope that undergoes the largest fractional change 
in the sequence of amino acids in comparison to the vaccine strain. A measurement of the 
epitope that is dominant in humans for various circulating strains and vaccines should 
help to improve the predictive power of our approach even more, as we can then use the 
measured dominant epitope to calculate pepitope instead of using our postulated dominant 
epitope. It is important to continue measurement and sequence analysis of the prominent 
circulating strains in the flu season. These data will help to validate and perhaps better 
calibrate the pepitope measure of antigenic distance. Another important piece of the puzzle is 
epidemiological study to relate vaccine efficacy to the antigenic drift. We believe that use 
of the pepitope measure of antigenic distance will enable the health authorities to predict the 
severity of the yearly flu season, to design better vaccines for the same, and help to 
manage the health resources for this period. 
 
In more general terms, the results presented here have implications for the fight against 
diseases that stem from rapidly mutating viruses and that are managed through antibody 
responses. The pepitope measure of antigenic distance can predict efficacies for vaccine 
strains against multiple circulating strains, and it could then be used towards redesigning 
of the vaccine in terms of frequency and composition. One such disease that has been 
threatening to turn into a pandemic of late is the avian influenza, or bird flu disease. In 
the next section, we present a multiple-strain transmission model for avian influenza that 
would enable one to manage the risk from such an outbreak. We use pepitope to evaluate the 
effectiveness of a multiple-component vaccine to counter such threat. 
 
Vaccination strategies and risk management of flu pandemic 
 
Since its first appearance (Hong Kong, 1997), H5N1 avian influenza is known to have 
spread to various parts of the world, including South-East Asian countries, parts of 
central and Middle-East Asia, Africa, and Europe. This rapid spread has prompted the 
World Health Organization (WHO) to suggest that “we are closer to a pandemic than at 
any time since 1968” [WHO report, 2005; Mills et. al., 2006]. Bird flu has been observed 
in pigs [Cyranoski, 2005], and occurrences of person-to-person transmission have likely 
been detected [Ungchusak et. al., 2005; Normile, 2006; Yang et. al., 2006]. Efficacy of 
the vaccine produced against the original Hong Kong strain of H5N1 has been poor 
against some of the new strains. In addition, the high mutation rates observed in the avian 
influenza have raised the prospect of simultaneous introduction of multiple strains [Mills 
et. al., 2006; Ducatez et. al., 2006; Chen et. al., 2006; Capua et. al., 2007], putting a 
question mark against the efficacy of a single-component vaccine. Although in the event 
of appearance of multiple strains, eventual emergence of a single dominant strain is 
likely; the lack of a priori knowledge of which strain will be dominant makes it 
worthwhile to look into the alternative of a multiple-component vaccine. Here, we use an 
epidemiological model to study the efficacy and cross-protection of a multiple-
  
component bird flu vaccine. We further extend the concept of pepitope through a stochastic 
model to manage the risk of a flu pandemic. The strategy is inspired by similar risk 
management studies in finance, and the population at risk for infection in an epidemic 
plays the role of the risk variable. Here pepitope represents the difference between circulating 
strains.  
 
Multiple-strain introduction transmission model 
 
As mentioned above, there is evidence, both theoretical and otherwise, that deems 
introduction of multiple-strains of avian influenza is a distinct possibility. There have 
been no mathematical models, however, that explore such a scenario to evaluate efficacy 
of practicable vaccine strategies. Our model uses the concepts of hierarchical scale free 
network, and virus transmission, and viral evolution to evaluate possible, and worst case, 
epidemic spreading scenarios and to evaluate efficacy of single or multiple-component 
vaccine strategies. 
 
Hierarchical scale free network 
 
We divide the total human population (6.7 x 109) into (6.7 x 106) groups. Each group 
consists of 103 people that exhibit similar health status and social behavior. These groups 
are distributed over Ncity cities. The distribution of cities with i groups (Ncity(i)) goes as 
Ncity(i) α  i-2.1 [Zipf, 1949; Newman, 2005]. The largest and the smallest city areas in our 
simulation have 6.2 x 104 and 400 groups respectively [Newman, 2005]. The total 
number of cities fluctuates around 4000 [Guimera et. al., 2005].  
 
The cities are connected through a network that extends globally and is defined by the 
network spawned by the airlines. The distribution of cities with i contacts is given by 
Ncity_contact(i) α  i-2.0. The network connecting groups within a city is defined by the 
ground transportation network. In each city, the distribution of groups with i contacts is 
given by Ngroup_contact(i) α  i-2.8 [Eubank et. al., 2004]. Population size differences between 
cities mean that movement from one city to another leads to a final averaged distribution 
over cities that is different for different contact numbers.  Any hierarchical structure 
present in the actual distributions of within- or between-city contacts, which is not 
detected by the scale-free analyses performed to date, would generally be expected to 
slow down the spread of an epidemic through the population. 
 
The scale free network is generated in two steps. The first step is to randomly assign a 
degree to each node based on the given power law distribution. This is achieved by the 
classical transformation method [Press et al., 2002]. The second step is to connect nodes. 
This is achieved by connecting nodes with a probability that is proportional to their 
degree. This scale free network generation method has been used in other scenarios 
[Albert et al.].  
 
Virus transmission and evolution 
 
  
In our simulation, the viruses are introduced in groups that are chosen randomly. The 
virus has a latency period of 2 days, which is followed by the infectious period. During 
the infectious period, the virus can either be killed by the host immune system, or it can 
be transmitted between different groups globally. During both these periods, the virus can 
mutate as well as be killed. The term Rmutation = 1.6 x 10-5/amino acid/day [Sato et. al., 
2006] gives the mutation rate, whereas, the virus killing probability is given by Kill_prob 
= cKill + cAlpha * max[(cEpiMax – epi), 0]. Here cKill is the intrinsic probability of 
killing virus, and its baseline value is fitted in our model to be 0.36. A value of 1.0 
proved to be optimal for cAlpha. cEpiMax is the largest possible epitope based distance 
between the vaccine strain and the current viral strain before the vaccine efficacy goes to 
zero, and its value is 0.19 [Gupta et. al., 2006]. The term epi is a function of the host 
immune history, and circulating virus strain. It is defined as the smallest distance among 
the epitope based distances between the current viral strain and the viral strains (50) in 
the immune history of the infected group. The transmission rate takes into account the 
seasonal effect [Ferguson et. al., 2003], and is different for transmission within a city 
(Ffac1×τ0× (1+0.25×Sin(2лT/360)), Ffac1=1.0) and transmission between cities 
(Ffac×τ0× (1+0.25), Ffac=7.0). FCap is the number of different groups that people 
travelling on a flight come from, and it is set to 100 for our model. The term τ0 is the 
intrinsic transmission ability of the virus, and equals 0.07 for the virus introduced on day 
1. The mutants, once created, can transmit according to probability cProb. For a baseline 
parameter, cProb equals 0.26. 
 
Vaccination Strategies 
 
As an example, for a very rapid public health policy response, we consider that after 40 
days, individuals are vaccinated. We consider single-component as well as multiple-
component vaccines. In single-component case, the most dominant strain at day 10 is 
taken as the vaccine strain, whereas, for multiple-component case, the top 10 strains that 
are most dominant on day 10 are incorporated into the vaccine. Day 10 is taken as the 
data collection day by public health authorities. We calculated the efficacy and the 
cumulative attack rates for both cases. Efficacy is defined by equation 2 above. Thus, 
efficacy represents the percentile reduction in disease occurrences in people who were 
vaccinated compared to those who were not [Nichol et. al., 1994; Chow, 2003].  
 
The model’s ability to predict an influenza pandemic was tested against the existing 
epidemiological data (figure 2a). The model successfully predicted the average trend of 
H3N2 isolates data in FluNet database of WHO from 1995 to 2006 (figure 2b).   We also 
successfully predicted the fixation rate for dominant and non-dominant epitopes of 
influenza (figure 3) versus those measured [Ferguson et. al., 2003]. 
 
WHO FluNet data analysis 
 
We acquired the WHO FluNet data for the period of 1995-2006 [WHO FluNet, 2006]. 
We separately averaged the isolates data for countries from the Northern and the 
Southern hemisphere over the 1997-2006 seasons [figure 2a]. For this duration, the 
annual flu epidemic seems to have several peaks. The highest peak occurs in summer. It 
  
is interesting to note the different epidemic dynamics in China, with an incidence peak in 
the summer, which is very different from other Northern hemisphere countries. China 
probably acts as a reservoir for the flu virus and also as a resource for transmission of the 
virus from pigs to humans in the summer. Thus, the summer peak in China is likely 
related to the role played by this virus reservoir. For each country for each year, we 
aligned the week with the highest peak, weekpeak, to week1 so that we could match the 
burst times for different years. This results in all data from a week preceding the peak 
week being shifted to (week52 – weekpeak), and all data from a week following the peak 
week being shifted to (weeki – weekpeak). After rearranging the data in such manner, we 
compared the results for average isolates from our simulation with those from the WHO 
FluNet data.  
 
Multiple-component vaccine 
 
We evaluated the viability of using a multiple-component vaccine against simultaneous 
introduction of multiple viral strains. In our model, we considered the possible scenario 
where two initial viruses, differing by pepitope, cause a pandemic. A pepitope value of zero 
indicates that viruses are the same, whereas a pepitope value of 1 indicates that the viruses 
are completely different. The model then predicted the efficacy of both single and 
multiple-component vaccines as a function of the pepitope (figure 4a). The cumulative attack 
rates are also predicted (figure 4b). A multiple-component vaccine was found to exhibit 
greater efficacy for the case where multiple-strains are introduced. There always exists a 
lag between viral outbreaks and administration of pertinent vaccine. We considered the 
effect such lag has on single and multiple-component vaccines. It was found that the lag 
affects single-component vaccine more than it affects multiple-component vaccine 
(figure 4c and 4d).  
 
Population at risk 
 
In order to manage the risk of possible introduction of multiple strains of avian influenza, 
we combined together our stochastic model and a bioinformatics study. Such risk 
management methods are in common use in financial institutions [Hull, 2005]. In 
economics, Value at Risk (VaR) is used as a metric in risk management studies. The term 
stands for the maximum loss over a given period of time with a certain confidence level. 
We use an analogous term, Population at Risk (PaR) in our study. It defines the 
maximum percentage of the world’s population that is at risk from viral infection in the 
event of an influenza pandemic over the period of one year with a confidence level. As an 
example, a PaR value of 0.1 at the 95% confidence level means that if there are 100 
pandemics, the maximum percentage of the global population that would be infected by 
the circulating viral strains in 95 of these pandemics stands at 0.1. The method could be 
applied to the risk management of infectious diseases in general. In the case of avian 
influenza, we analyzed all H5N1 strains in the National Center for Biotechnology 
Information (NCBI) database [NCBI database, 2007], and calculated the pepitope for all 
pairs of the viral strains. The average value turned out to be pepitope = 0.118. We generated 
two initial viruses using the pepitope value, and carried out simulations for 2000 yearly 
pandemics for 3 cases: with no vaccination, vaccination with single-component vaccine, 
  
and vaccination with multiple-component vaccine. The PaR was calculated for 
confidence interval between 0.9 and 0.99. As seen from figure 5, our model is able to 
predict the virus transmission (figure 5a) and basic production number (figure 5b). It also 
shows that the fewer the vaccine components, the more the number of people that get 
infected in these pandemics (figure 5c). This clearly shows that a multiple-component 
vaccine not only improves the efficacy of a vaccine, but is also important to manage 
worse case scenarios. 
 
Summary 
 
We have developed a pandemic model for avian influenza. Virus evolution, inter-
personal transmission, vaccination, and immune history are taken into account. The 
model is able to reproduce the observed data for H3N2 isolates. Vaccination against 
multiple-components is not a foregone conclusion in case of simultaneous introduction of 
multiple strains. The parameter pepitope, helps decide if use of multiple-component vaccine 
is likely to be beneficial. The pepitope measure of antigenic distance also helps decide what 
strains to incorporate in the vaccine under such scheme. The model shows that a vaccine 
with multiple-components outperforms a single-component vaccine when there are 
greater than one circulating strains that are antigenically different from each other. The 
model also shows that compared to the traditional single-component vaccine, a multiple-
component vaccine is affected to a lesser degree by the lag between viral outbreak and 
vaccine administration. This result has important implications if there is a sudden attack 
of avian influenza pandemic, and the process of designing, producing, delivering, and 
administrating a vaccine is delayed significantly. The model proves that the spread of the 
virus is contingent upon number of emergent strains, fraction of the population 
vaccinated, and the time of administration of the vaccine following the outbreak. Lastly, 
the model provides a new parameter, PaR, that foretells how severe a potential epidemic 
could be. Combined with multiple-component vaccine, PaR would be valuable to 
quantify the benefit from actual vaccination strategies, beyond the broad notion of 
addressing multiple isolates. One can calculate virus differences through WHO FluNet to 
get an average pepitope value that could be used in our model. The model can yield PaR 
values for different areas of the world. The results of PaR calculation could alert the 
policy makers and general public of the current pandemic risk level, and along with pepitope 
calculations also help pharmaceutical companies to prepare optimal vaccine components. 
An improved predictive ability regarding the extent of impending epidemic and 
appropriate vaccine design would enhance our ability to better manage precious public 
health resources.  
 
Appendix: 
 
Sensitivity analysis 
 
We carried out a sensitivity analysis of the model for all parameters for figure 5. A 
sensitivity analysis is important for model verification. It also indicates to which public 
health policy measures an influenza outbreak may be most sensitive. First, we did 
sensitivity analysis for the network structure. The variable parameters were the exponents 
  
in the power law relation of population distribution (Ncity), group distribution 
(Ngroup_contact) and flight distribution (Ncity_contact). For the population distribution, when the 
exponent was decreased by 5%, the cumulative attack rate was reduced by 41%, and 
when the exponent was increased by 5%, the cumulative attack rate was increased by 
62%. For the group distribution, when the exponent was decreased by 4%, the cumulative 
attack rate was increased by 27%, and it decreased by 19% for an increase of the same 
magnitude in the variable. The epidemic curve remained practically unaffected for 
changes in both these variables. For the flight distribution, a 2.5% decrease in the 
exponent caused a jump of nearly 85%, and an increase of 2.5% in the same variable 
caused a decrease of 50% in the cumulative attack rate. In the epidemic trend, one can see 
the average isolations decrease almost 50% at week 40, for an increase of 2.5% in the 
exponent value.   
 
We checked the model’s sensitivity against the flight transportation parameters. A change 
of 7% in Ffac in either direction resulted in a proportional change of 28% in the 
cumulative attack rate. The epidemic trend curve was practically unchanged, with only a 
small jump in average isolations around week 40 with increasing Ffac. A change of 8% in 
either direction for ffactor1 also resulted in proportional change of 7% for the cumulative 
attack rate. The epidemic curve remained unaltered for these changes. When FCap was 
decreased by 15%, the cumulative attack rate was decreased by 43%, and when FCap was 
increased by 15%, the rate jumped by 65%. The cumulative attack rate has a non-linear 
relationship with the FCap. The epidemic curve was affected by these changes in FCap. 
Around week 10, and week 40, the average cases increased up to two fold, when FCap 
increased from 100 to 115. Reducing air travel would seem to be effective for mitigating 
an influenza epidemic. 
 
Sensitivity analysis was carried out for the initial virus transmission probability, τ0, the 
immune killing, cKill, and for the immune history capacity. For a 7% change in τ0, the 
cumulative attack rate changed by nearly 40%. The function increased linearly with the 
variable. The epidemic trend saw almost two-fold jump at week 40 in the average cases. 
The cumulative attack rate increased nearly 39% when cKill decreased by 6%. It 
decreased by 32% for an increase of same magnitude in cKill. The epidemic trend 
showed nearly 50% reductions in average cases at week 40, for a 6% increase in cKill. 
The cumulative attack rate remained independent of the immune history capacity. A two 
fold increase in the parameter brought about 1% decrease in the attack rate. The epidemic 
trend remained unaltered. Measures such as face masks would seem to be effective. 
 
Next, we checked the dependence of the cumulative attack rate on the mutation rate, 
Rmutation, and the transmission probability of the mutants, cProb. A two-fold increase in 
Rmutation rendered the cumulative attack rate the same (<1% change). A two-fold decrease 
in the variable yielded the same result. The epidemic trend saw nearly 3-fold increase in 
the average isolations around week 40 when Rmutation was doubled. The cProb parameter, 
when decreased by 50%, saw a decrease of 1% in the cumulative attack rate, but when 
the parameter was increased two-fold, the cumulative attack rate jumped by nearly 10%. 
This indicated a non-linear relationship between the function and the variable. The 
  
epidemic trend showed nearly 3 times increase in the average cases at week 40 when the 
parameter was doubled.                               
     
We changed the initially infected group number. The sensitivity analysis showed that 
doubling the number of initially infected groups pushed the cumulative attack rate up by 
22%, whereas halving the value of the parameter decreased the attack rate by nearly 13%. 
The epidemic trend curve remained unchanged for these variations. 
 
The fixation rate depends up on the mutation rate, Rmutation, and the mutation transmission 
probability, cProb, the most. We carried out a sensitivity analysis against these two 
variables. For both the parameters for non-dominant epitopes, the fixation rate stayed 
relatively flat. However, for the dominant epitope, the fixation rate nearly doubled with a 
two-fold increase in the variable. 
 
We carried out sensitivity tests for single-component vaccine at pepitope = 0.0 and pepitope = 
1.0, and for multiple-component vaccine at pepitope = 1.0, both at day 40 with 40% of the 
population vaccinated.  
 
The network structure parameter (exponent for population distribution) affects 
cumulative attack rate and efficacy. The cumulative attack rate increases while efficacy 
decreases with increasing value of the parameter. For the case of pepitope = 1.0, a change of 
5% in the parameter results in 2 to 4 fold change in the cumulative attack rate for both 
single and multiple-component vaccines. A similar trend is seen for the case of pepitope = 
0.0 for single-component vaccine. The efficacy drops by 6 to 7% for multiple-component 
vaccine at pepitope = 1.0 as well as for single-component vaccine at pepitope = 0.0, and it drops 
by around 10% for the single-component vaccine at pepitope = 1.0 for every 5% increase in 
the value of the network structure parameter. 
 
We checked the sensitivity of cumulative attack rate and efficacy against exponent of 
flight distribution. Once again, in terms of absolute values, a multiple-component vaccine 
outperforms a single-component vaccine over the tested range of the parameter. The 
cumulative attack rate decreases with increasing value of the variable. For the case of 
pepitope = 1.0, a change of 4% in the parameter results in 40% to 50% change in the 
cumulative attack rate for both single and multiple-component vaccines. A similar trend 
is observed for the case of pepitope = 0.0 for a single-component vaccine. For pepitope = 1.0, 
and for the same change in the parameter, the efficacy of single-component vaccine 
increases around 4%, and that of multiple-component vaccine increases by about 5%, 
whereas, for pepitope = 0.0, the efficacy for the single-component vaccine increases by 5%. 
 
Sensitivity analysis of the flight transportation parameter gives the following results. In 
the case that pepitope = 1.0, when we change Ffac by 7%, the cumulative attack rate changes 
by around 40% for the multiple-component vaccine, and it changes by 45% for the 
single-component vaccine. The efficacy drops by 6% for the multiple-component case, 
and it drops by nearly 10% for the single-component vaccine. When pepitope = 0.0, the 
cumulative attack rate of the single-component vaccine changes by nearly 50%, and its 
  
efficacy changes by nearly 5% for a 7% change in  Ffac. The attack rate increases, 
whereas, efficacy decreases with increase in the value of Ffac. 
 
With FCap as the variable, the sensitivity analysis shows that for the case of pepitope = 1.0, 
with a 15% increase, the cumulative attack rate more than doubles, and efficacy drops by 
15% for the multiple-component vaccine, and the cumulative attack rate doubles, and 
efficacy drops by nearly 13% for the single-component vaccine. For the case of pepitope = 
0.0, there is a two-fold increase, and a 15% decrease for cumulative attack rate and 
efficacy, respectively.  
 
We analyzed the sensitivity of our model to the virus transmission probability, τ0. For the 
case of pepitope = 1.0, and both for multiple as well as single-epitope vaccine, the 
cumulative attack rate changes nearly 50% for a 7% change in the value of τ0. The 
efficacy varies 6% and 12% respectively for the two cases. For the case of pepitope = 0.0, 
the single-component vaccine sees cumulative attack rate change 50% and efficacy 
change 6% for a 7% change in the value of τ0. The attack rate increases, and efficacy 
decreases with increasing τ0. 
 
For the case of pepitope = 1.0, a change of 6% in intrinsic killing probability, cKill, changes 
the cumulative attack rate by 3 fold, and 2.5 fold respectively, for multiple and single-
component vaccines. Efficacy changes by 14% in multiple-component vaccine, and by 
18% in single-component vaccine. When pepitope = 0.0, the cumulative attack rate changes 
3 fold, and efficacy changes 14% for single-component vaccine for a similar change in 
cKill. Once again, attack rate increases, and efficiency decreases with increase in cKill.  
 
Sensitivity analysis was also applied to the mutation rate, Rmutation. With pepitope = 1.0, 
cumulative attack rate changes by 15% in multiple-component, and by 10% in single-
component vaccine. For multiple-component vaccine, a drop in Rmutation by 50% increased 
the efficacy by 7%, but a two-fold increase in Rmutation decreased the efficacy by 13%. A 
similar trend was observed for a single-component vaccine. For the case of pepitope = 0.0, a 
50% decrease in Rmutation raised the cumulative attack rate by nearly 25%, and reduced 
efficacy by nearly 3%. A two-fold increase in Rmutation on the other hand raised the attack 
rate by 25%, but reduced efficacy by nearly 16%. 
 
Finally, sensitivity analysis of the mutant transmission probability, cProb, yielded the 
following results. When pepitope = 1.0, a two-fold increase in cProb brings 17% and 10% 
increase in the cumulative attack rate of multiple and single-component vaccines 
respectively. For the same change in cProb, efficacies drop by 7%, and 4% for multiple 
and single-component vaccines respectively. When pepitope = 0.0, for a two-fold change in 
cProb, the cumulative attack rate of the single-component vaccine shows a jump of 
around 25%. The efficacy drops by around 7% for the same change in cProb.  
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Table 1: Summary of results for  pepitope Analysis [Gupta et. al., 2006]; Individual references also provided below. 
Year Vaccine strain Circulating strain Vaccine efficacy(%)  Dominant epitope pepitope psequence d1 d2 Nu Nv 
1971-1972 Aichi/2/68(V01085) HongKong/1/68(AF20
1874) 7 [Smith et. al., 1979] A 0.158 0.033   25202 26317 
1972-1973 Aichi/2/68(V01085) England/42/72(AF201
875) 
15 [ Smith et. al., 
1979] B 0.190 0.055   26130 26778 
1973-1974 England/42/72(ISDNE
NG72) 
PortChalmers/1/73(A
F092062) 
11 [ Smith et. al., 
1979] B 0.143 0.018 
5 [Smith et. al., 
1999] 
4 [Smith et. al., 
1999] 26536 28158 
1975-1976 PortChalmers/1/73(A
F092062) 
Victoria/3/75(ISDNVI
C75) 
-3 [ Smith et. al., 
1979] B 0.190 0.055 
4 [Kendal et. al., 
1983] 
16 [Kendal et. 
al., 1983] 25591 29247 
1984-1985 Philippines/2/82(AF23
3691) 
Mississippi/1/85(AF00
8893) 
-6 [Keitel et. al., 1988] B 0.190 0.033 2 [WHO, 1988] 2 [ WHO, 1988] 241 171 
1985-1986 Philippines/2/82(AF23
3691) 
Mississippi/1/85(AF00
8893) 
-2 [Keitel et. al, 1997; 
Demicheli et.al., 2004] B 0.190 0.033 2 [ WHO, 1988] 2 [ WHO, 1988] 25391 15388 
1987-1988 Leningrad/360/86(AF
008903) 
Shanghai/11/87(AF00
8886) 
17 [Edwards et. al., 
1994;  Keitel et. al., 
1997] 
B 0.143 0.024 2 [ WHO, 1988] 1 [ WHO, 1988] 1451064 1211060 
1989-1990 Shanghai/11/87(AF00
8886) 
England/427/88(AF20
4238) 
-5 [Edwards et. al., 
1994] A 0.105 0.021   1016 1016 
1992-1993 Beining/32/92(Af0088
12) 
Beining/32/92(Af0088
12) 
59 [Campbell et. al., 
1997]  0.0 0.0 
0 [Ellis et. al., 
1995] 
0 [Ellis et. al., 
1995] 131 131 
1993-1994 Beining/32/92(Af0088
12) 
Beining/32/92(Af0088
12) 
38 [Demicheli et. al., 
2004]  0.0 0.0 
0 [Ellis et. al., 
1995] 
0 [Ellis et. al., 
1995] 12 26 
1994-1995 Shangdong/9/93(Z46
417) 
Johannesburg/33/94(
AF008774) 
25 [Nichol et. al., 
1995] A 0.108 0.021   424 422 
1995-1996 Johannesburg/33/94(
AF008774) 
Johannesburg/33/94(
AF008774) 
45 [Grotto et. al., 
1998]  0.0 0.0 
0 [CDC, 1997; 
Corias et. al., 
2001] 
0 [CDC, 1997; 
Corias et. al., 
2001] 
652 684 
1996-1997 Nanchang/933/95(AF
008725) 
Wuhan/359/95(AF008
722) 
28 [Millot et. al., 2002] 
B 0.095 0.006 
0 [CDC, 1997; 
Corias et. al., 
2001] 
0 [CDC, 1997; 
Corias et. al., 
2001] 
2978 273 
1997 Nanchang/933/95(AF
008725) 
Wuhan/359/95(AF008
722) 
11 [Mixeu et. al., 
2002] B 0.095 0.006 
0 [CDC, 1997; 
Corias et. al., 
2001] 
0 [CDC, 1997; 
Corias et. al., 
2001] 
299 294 
1997-1998 Nanchang/933/95(AF
008725) 
Sydney/5/97(AJ31146
6) 
-17 [Bridges et. al., 
2000] B 0.238 0.040 
4.5 [Corias et. 
al., 2001; 
Pontoriero et. al., 
2001] 
27.3 [Corias et. 
al., 2001; 
Pontoriero et. al., 
2001] 
554 576 
1998-1999 Sydney/5/97(AJ31146
6) 
Sydney/5/97(AJ31146
6) 
34 [Bridges et. al., 
2000]  0.0 0.0 
0 [Corias et. al., 
2001; Cox wt. 
al., 2003] 
0 [Corias et. al., 
2001; Cox wt. 
al., 2003] 
596 582 
1999-2000 Sydney/5/97(AJ31146
6) 
Sydney/5/97(AJ31146
6) 
43 [Lester et. al., 
2003]  0.0 0.0 
0 [Corias et. al., 
2001; Cox wt. 
0 [Corias et. al., 
2001; Cox wt. 324 342 
  
The definitions for pepitope, psequence are described previously (fractional change in the immunodominant epitope and fractional change in the whole sequence 
respectively). The terms d1 and d2 are the two available measures of distance based on ferret anti-serum. Figures below are to provide the analysis of the data 
presented in the table. The bracketed numbers are the references used. When more than one antisera assay has been performed, the calculated distances are 
averaged. Error bars are calculated assuming binomial statistics for each data set: ε2 = [σv2/u2/Nv + (v/u2)2 σu2/ Nu], where σv2 = v(1-v) and σu2 = u(1-u) If two sets 
of data are averaged in 1 year, then ε2 =  ε12/4 + ε22/4.      
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Figure 1: Vaccine efficacy for influenza-like illness as observed in epidemiological 
studies as a function of three different measures of antigenic distance (Gupta et. al., 
2006). A linear least squares fit to the data is also shown. Error bars are one standard 
error ε, calculated as described in Table 1. (a) pepitope: (long dashed, R2=0.81). (b) psequence: 
(long dashed, R2=0.59). Figure shows the same epidemiological data as in (a). Only the 
definition of the x-axis is different. (c) d1 (long dashed, R2=0.57) and d2 (short dashed, 
R2=0.43), derived from ferret antisera experiments. Results were averaged when multiple 
hemagglutinin inhibition (HI) studies had been performed for a given year. These HI 
binding arrays measure the ability of ferret antisera to block the agglutination of red 
blood cells by influenza viruses. The epidemiological data is same as in figure (a). Only 
the definition of the x-axis is different. 
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                                                 (b) 
 
Figure 2: Average isolates cases of human H3N2 influenza. (a) Cases reported during last 
10 years for various countries around the world. (b) Comparison between the WHO 
FluNet database and as predicted by our immunological and epidemiological model. 
 
 
  
 
Figure 3: Influenza fixation rate for dominant and non-dominant epitopes. Dominant: 
fixation rate for dominant epitope from simulation, Non-dominant: fixation rate for non-
dominant epitopes from simulation; Dominant1: fixation rate and error bar for dominant 
epitopes from sequence analysis [Ferguson et. al., 2003], Non-dominant1: fixation rate 
and error bar for non-dominant epitope from sequence analysis [Ferguson et. al., 2003].           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                             (a)                                                                   (b) 
 
 
(c) (d) 
 
Figure 4: The effect of a vaccine for the initial introduction of two-strains. This indicates 
the multiple-component vaccine excels single-component vaccine for different 
vaccination day and vaccination populations. Sc: single-component vaccine. Mc: 
multiple-component vaccine. V: vaccination population over total population. Vac Day: 
The day when vaccine is administered. Vaccination population dependency at Vac Day = 
40: (a) Efficacy as a function of pepitope for single and multiple component vaccines with 
different vaccination populations. (b) Cumulative attack rate as a function of pepitope. 
Vaccination day dependence at V=40%: (c) Efficacy as a function of pepitope. (d) 
Cumulative attack rate as a function of pepitope. 
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                                        (b) 
 
                                      (c) 
Figure 5: Virus transmission, basic production number, and Population at Risk (Par) from 
our immunological and epidemiological model. (a) Averaged infectious cases. (b) The 
basic production number (R0). (c) Population at Risk (PaR) over a year for three cases: 
without vaccination, single-component vaccination, and multiple-component vaccination. 
  
